BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 31779047)

  • 1. Successful treatment of an elderly patient with an uncommon L861Q epidermal growth factor receptor mutation with low-dose afatinib: A case report.
    Iida Y; Kumasawa F; Shimizu T; Shintani Y; Takahashi N; Gon Y
    Thorac Cancer; 2020 Feb; 11(2):447-450. PubMed ID: 31779047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Durable complete response after afatinib and crizotinib in an advanced non-small cell lung cancer patient with EGFR L861Q mutation and acquired MET amplification: a case report.
    Long Y; Zhang K; Li Y; Yu M; Zhu J; Huang M
    Ann Palliat Med; 2020 Sep; 9(5):3609-3613. PubMed ID: 32648452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Limited effect of afatinib in a non-small cell lung cancer patient harboring an epidermal growth factor receptor K860I missense mutation: A case report.
    Tamura T; Kawakado K; Makimoto G; Nakanishi M; Kuyama S
    Thorac Cancer; 2021 Jun; 12(11):1770-1774. PubMed ID: 33942527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line Afatinib in Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in South Korea.
    Kim MH; Choi CM; Lee SY; Park CK; Chang YS; Lee KY; Kim SJ; Yang SH; Ryu JS; Lee JE; Lee SY; Park CK; Lee SH; Jang SH; Yoon SH; Jang TW
    Anticancer Res; 2022 Mar; 42(3):1615-1622. PubMed ID: 35220259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and Tolerability of First-Line Afatinib for Advanced EGFR-Mutant Non-Small Cell Lung Cancer in Vietnam.
    Vu TH; Nguyen HTT; Dao LK; Duong CK; Nguyen CV; Doan TT; Nguyen HTT; Hoang HH; Dinh DK; Le GV; Vu TT; Truong MC; Nguyen LT
    Asian Pac J Cancer Prev; 2021 May; 22(5):1581-1590. PubMed ID: 34048189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term response to afatinib in an elderly patient with uncommon epidermal growth factor receptor mutation-positive lung adenocarcinoma.
    Shijubou N; Sumi T; Kamada K; Sawai T; Yamada Y; Nakata H; Mori Y; Chiba H
    Thorac Cancer; 2021 Mar; 12(6):989-992. PubMed ID: 33533191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment of triple EGFR mutation T785A/L861Q/H297_E298 with afatinib.
    Longo V; Catino A; Montrone M; Pizzutilo P; Pesola F; Marech I; Capone I; Prelaj A; Galetta D
    Thorac Cancer; 2021 Jul; 12(13):2031-2034. PubMed ID: 34008923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402).
    Yokoyama T; Yoshioka H; Fujimoto D; Demura Y; Hirano K; Kawai T; Kagami R; Washio Y; Ishida T; Kogo M; Tomii K; Okuno T; Akai M; Hirabayashi M; Nishimura T; Nakahara Y; Kim YH; Miyakoshi C; Yoshimura K; Hirai T;
    Lung Cancer; 2019 Sep; 135():175-180. PubMed ID: 31446992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Activity of Afatinib in Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study.
    Moran T; Taus A; Arriola E; Aguado C; Dómine M; Rueda AG; Calles A; Cedrés S; Viñolas N; Isla D; Palmero R; Sereno M; Diaz V; Juan O; Marsé R; Martorell PM; Sánchez Torres JM;
    Clin Lung Cancer; 2020 Sep; 21(5):428-436.e2. PubMed ID: 32461037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful afatinib rechallenge in a patient with non-small cell lung cancer harboring EGFR G719C and S768I mutations.
    Masuda T; Sunaga N; Kasahara N; Takehara K; Yatomi M; Hara K; Koga Y; Maeno T; Hisada T
    Thorac Cancer; 2020 Aug; 11(8):2351-2356. PubMed ID: 32529804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and potential resistance mechanisms of afatinib in advanced non-small cell lung cancer patients with EGFR G719X/L861Q/S768I.
    Pang LL; Gan JD; Tan JR; Huang YH; Liao J; Liang WT; Deng PB; Fang WF
    Cancer; 2022 Nov; 128(21):3804-3814. PubMed ID: 36069292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitivity of epidermal growth factor receptor with single or double uncommon mutations to afatinib confirmed by a visual assay.
    Kimura S; Tanaka K; Harada T; Liu R; Shibahara D; Kawano Y; Nakanishi Y; Okamoto I
    Cancer Sci; 2018 Nov; 109(11):3657-3661. PubMed ID: 30255614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Afatinib for the treatment of
    Harvey RD; Adams VR; Beardslee T; Medina P
    J Oncol Pharm Pract; 2020 Sep; 26(6):1461-1474. PubMed ID: 32567494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review.
    Jiang Y; Fang X; Xiang Y; Fang T; Liu J; Lu K
    Curr Oncol; 2023 May; 30(6):5337-5349. PubMed ID: 37366888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful Treatment of a Patient with Lung Adenocarcinoma Harboring Compound EGFR Gene Mutations, G719X and S768I, with Afatinib.
    Kutsuzawa N; Takahashi F; Tomomatsu K; Obayashi S; Takeuchi T; Takihara T; Hayama N; Oguma T; Aoki T; Asano K
    Tokai J Exp Clin Med; 2020 Sep; 45(3):113-116. PubMed ID: 32901897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
    Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
    Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Afatinib, an effective treatment for patient with lung squamous cell carcinoma harboring uncommon EGFR G719A and R776C co-mutations.
    Han C; Ding X; Li M; Luo N; Qi Y; Wang C
    J Cancer Res Clin Oncol; 2022 May; 148(5):1265-1268. PubMed ID: 35230510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful Treatment of Lung Adenocarcinoma with Epidermal Growth Factor Receptor Compound Mutations Involving Exon 19 Deletion and Exon 20 Insertion by Afatinib.
    Ikeuchi T; Tokuyasu H; Ishikawa S
    Intern Med; 2019; 58(1):101-104. PubMed ID: 30606938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.
    Heigener DF; Schumann C; Sebastian M; Sadjadian P; Stehle I; Märten A; Lüers A; Griesinger F; Scheffler M;
    Oncologist; 2015 Oct; 20(10):1167-74. PubMed ID: 26354527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?
    Banno E; Togashi Y; Nakamura Y; Chiba M; Kobayashi Y; Hayashi H; Terashima M; de Velasco MA; Sakai K; Fujita Y; Mitsudomi T; Nishio K
    Cancer Sci; 2016 Aug; 107(8):1134-40. PubMed ID: 27240419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.